info@amda-pompe.org

Changing Lives—UTSA Sombrilla

Jul 20, 2009 | EDITORIALS

By: Jason B. Johnson posted on: July 20, 2009 Published in University of Texas San Antonio’s Sombrilla Magazine: Summer 2009 Tiffany House was just 11 when she was diagnosed with a rare and often fatal disease called Acid Maltase Deficiency. Doctors told her she...

Genzyme Submits All Information Requested by FDA for Lumizyme

May 22, 2009 | NEWS

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has submitted the final documentation to address all items in the FDA’s complete response letter for LumizymeTM (alglucosidase alfa), produced at the 2,000 L bioreactor scale. The submission...

IPA Statement: The End Of Myozyme Supply Restrictions

May 8, 2009 | EDITORIALS

By: IPA posted on: May 08, 2009 Dear IPA Affiliate, You will no doubt have heard the wonderful news that Myozyme from the Belgian production facility has been approved for patients within the European Community (see the IPA website for the press release). Another...

IPA Statement: The End of Myozyme Supply Restrictions

May 8, 2009 | NEWS

Dear IPA Affiliate, You will no doubt have heard the wonderful news that Myozyme from the Belgian production facility has been approved for patients within the European Community (see the IPA website for the press release). Another great success has been the adoption...

Pompe Program Update from Genzyme

Mar 3, 2009 | NEWS

Supply Update In January 2009, Genzyme notified the Pompe community that we were experiencing a temporary constraint in the global supply of Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale and that inventories were extremely tight. We are pleased...